TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 ...
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6 ...